A phase II trial of the new immunotherapy agent, Alzheimer's disease vaccine [AN-1792],

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1326, 2002-01, pp. : 20-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Developments of Clinical Trial in Immunotherapy for Alzheimer's Disease

Current Pharmaceutical Biotechnology, Vol. 16, Iss. 6, 2015-01 ,pp. : 484-491

Bentham Science Publishers

Access to resources Recommend Favorite

Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine

Current Pharmaceutical Design, Vol. 22, Iss. 7, 2016-02 ,pp. : 849-858

Bentham Science Publishers

Access to resources Recommend Favorite

New hope for Alzheimer's disease vaccine

Inpharma, Vol. 1, Iss. 1369, 2003-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Vaccine Development for Alzheimer's Disease

Current Pharmaceutical Design, Vol. 12, Iss. 33, 2006-11 ,pp. : 4283-4293

Bentham Science Publishers

Access to resources Recommend Favorite

Immunotherapy in a Rabbit Model of Alzheimer’s Disease

By S. Woodruff-Pak Diana Shriver Christina Agelan Alexis M. Manns Joanne Coico Richard

Drug Delivery Letters, Vol. 2, Iss. 1, 2012-03 ,pp. : 14-21

Bentham Science Publishers

Access to resources Recommend Favorite